Proliferative Polycythaemia

Polycythaemia vera is a long-lasting blood cancer. Your bone marrow makes too many red blood cells. Sometimes white cells and platelets are high too. The blood becomes thicker. Thick blood moves slowly and can form clots. Clots can cause stroke, heart attack, deep-vein thrombosis, or pulmonary embolism. Most people with PV have a change (mutation) in a gene called JAK2. This faulty signal tells marrow cells to grow and divide all the time. PV usually grows slowly for many years. The main goal of care is to prevent clots and ease symptoms like headache, dizziness, itching, night sweats, and tiredness. Keeping the hematocrit (Hct) below 45% lowers the chance of serious events. NatureNew England Journal of Medicine

Proliferative polycythaemia almost always means polycythaemia vera (PV). PV is a slow-growing blood cancer of the bone marrow. The marrow makes too many red blood cells, and often too many white cells and platelets as well. The extra cells make the blood thick. Thick blood flows more slowly and can clot more easily. PV happens because of a change (mutation) in a gene called JAK2 inside blood-forming stem cells. This change keeps the JAK-STAT signal “on,” so the marrow keeps making cells even when the body does not need them. Doctors diagnose PV with blood tests, bone-marrow tests, and gene tests (mainly JAK2 V617F or JAK2 exon 12). A key lab clue is a low erythropoietin (EPO) level in the blood. NCBIPMCMedscapeMerck Manuals

Other names

Polycythaemia vera; primary polycythaemia; Osler–Vaquez disease; polycythaemia rubra vera; erythremia/erythraemia. All of these names mean the same disease. Cleveland ClinicWikipedia

Types and stages

1. Classic / overt PV – obvious high haemoglobin/haematocrit; JAK2 mutation present.

2. Masked PV – red cells are truly increased but measured haemoglobin/haematocrit can look normal or only slightly high (for example, because of iron lack); RCM or marrow/genetic testing reveals PV.

3. JAK2 V617F–positive PV – the most common molecular form.

4. JAK2 exon 12–positive PV – less common; often strong erythrocytosis in younger or lean patients.

5. Post-PV myelofibrosis (“spent phase”) – late phase when marrow becomes scarred and spleen enlarges.
   (“Types” are practical groupings used in clinics and papers rather than official separate diseases.) PMC+2PMC+2

---

Causes

Important note: PV has one fundamental cause—an acquired JAK2 mutation in marrow stem cells. The items below explain (A) the true cause and biologic drivers inside PV, and (B) look-alike causes of erythrocytosis that doctors must rule out because they can mimic PV but are not PV.

A. True cause and disease drivers in PV

1. JAK2 V617F mutation (driver cause). Present in ~95% of PV and turns on JAK-STAT signalling, driving cell overgrowth. NCBIAsh Publications

2. JAK2 exon 12 mutations. Account for a minority of PV when V617F is negative; also activate JAK-STAT. PMC

3. JAK2 46/1 (“GGCC”) germline haplotype (predisposition). A common inherited background that makes JAK2 mutations more likely to appear. It does not cause PV by itself but raises risk. PMCNature

4. Epigenetic co-mutations (TET2). Can coexist with JAK2; may influence clot risk and disease behaviour. PMC

5. Epigenetic co-mutations (ASXL1). Occur in a subset of PV and may relate to more advanced biology. Wiley Online Library

6. Epigenetic co-mutations (DNMT3A). Another common partner mutation that can shape disease course. Wiley Online Library

7. Less frequent co-mutations (EZH2, IDH1/2, spliceosome genes such as SF3B1/SRSF2). Seen in smaller fractions; may affect progression risks. Wiley Online Library

8. Constitutive JAK-STAT signalling in erythroid cells. Makes red-cell precursors grow with little or no EPO stimulation. NCBI

9. Bone-marrow panmyelosis (all three lines grow). Not a separate cause but a core biologic feature explaining leukocytosis and thrombocytosis in PV. Medscape

10. Low serum EPO (feedback effect). The body reduces EPO because the marrow over-produces; this is a marker that supports PV diagnosis. Haematologica

B. Look-alike causes of erythrocytosis to exclude

11. Chronic low oxygen (lung disease, heart disease, high altitude). Triggers high EPO and secondary erythrocytosis. NCBI

12. Obstructive sleep apnoea. Night-time hypoxia raises EPO and red-cell mass. NCBI

13. Smoking/carboxyhaemoglobin. Carbon monoxide lowers oxygen delivery and drives erythrocytosis. Medscape

14. High-oxygen-affinity haemoglobin variants (low P50). Red cells hold oxygen too tightly; body compensates by making more red cells. PMC

15. 2,3-BPG deficiency (rare). Shifts the O2 curve left like high-affinity Hbs; raises red cells. UCSD Internal Medicine Residency

16. Exogenous EPO or androgens (testosterone). Medications/supplements increase red-cell production. Frontiers

17. EPO-secreting tumours (kidney, liver, cerebellum). Produce excess EPO and cause secondary erythrocytosis. Frontiers

18. Renal hypoxia/renal artery stenosis/cysts. Kidney senses low oxygen and releases more EPO. Frontiers

19. Post-renal-transplant erythrocytosis. A known secondary form after transplant. NCBI

20. Relative (plasma-volume) polycythaemia (dehydration/diuretics). Looks like high haematocrit but red-cell mass is normal. NCBI

---

Common symptoms and signs

1. Headache and “heavy” head. Thick blood reduces smooth flow in brain vessels, causing pressure-type headaches. Mayo Clinic

2. Dizziness or light-headedness. Sluggish flow means less steady oxygen delivery. AAFP

3. Tiredness/fatigue. A very common, non-specific symptom in PV. Mayo Clinic

4. Itching after a warm shower/bath (aquagenic pruritus). Triggered by water/temperature change; linked to mast cells and basophils. PubMedMedscape

5. Burning pain and redness in hands/feet (erythromelalgia). Small-vessel flow problems cause hot, painful, red skin areas. AAFP

6. Blurred vision or visual “sparkles.” From tiny vessel spasm or sluggish retinal flow. AAFP

7. Ruddy face or flushed skin (plethora). Extra red cells give a red-purple tone to skin and lips. Mayo Clinic

8. Nosebleeds, gum bleeding, easy bruising. Platelet dysfunction and acquired von Willebrand factor problems can appear even with high platelet counts. Merck Manuals

9. Left-upper-belly fullness or early satiety. Often from an enlarged spleen. AAFP

10. Gout or kidney stones. Extra cell turnover raises uric acid. Medscape

11. High blood pressure. Thick blood and vascular stiffness can raise readings. Mayo Clinic

12. Shortness of breath or chest pain. May reflect clots or reduced flow; urgent care if sudden or severe. Mayo Clinic

13. Numb or tingling fingers/toes. Small-vessel issues can irritate nerves. AAFP

14. Night sweats and unintentional weight loss. Less common constitutional symptoms in myeloproliferative diseases. NCBI

15. Clotting events (stroke/TIA, DVT, pulmonary embolism, splanchnic vein thrombosis). The most serious complications; risk rises with age and past clots. PMC

---

Diagnostic tests

A) Physical examination

1. General look for “plethora.” A ruddy, red-purple face/lips suggests high red-cell mass. Mayo Clinic

2. Blood pressure measurement. Hypertension is common and increases clot risk. Mayo Clinic

3. Abdominal palpation for spleen. Feel for an enlarged spleen below the left rib margin; common in PV over time. (Imaging confirms.) AAFP

4. Skin and extremity check. Look for scratches from itch, and for red, hot, painful toes/fingers (erythromelalgia). AAFP

B) Manual bedside tests

5. Spleen percussion (e.g., Castell’s/Traube’s methods). Simple bedside ways to screen for splenic enlargement before imaging. (Ultrasound is the confirmatory test.) AAFP

6. Capillary refill time (nail-bed). A quick check of micro-circulation; delayed refill may reflect sluggish flow.

7. Orthostatic vital signs. Helps distinguish true erythrocytosis from relative polycythaemia due to low plasma volume (dehydration), which may show postural changes. NCBI

C) Laboratory & pathological tests

8. Complete blood count (CBC). Shows high haemoglobin/haematocrit; often leukocytosis and thrombocytosis from panmyelosis. Medscape

9. Peripheral blood smear. Looks at cell shapes/numbers; supports CBC findings and rules out other disorders. Medscape

10. Serum erythropoietin (EPO) level. Often low in PV and helps separate PV from secondary erythrocytosis (which usually has normal/high EPO). HaematologicaCleveland Clinic Journal of Medicine

11. JAK2 V617F mutation test (PCR/NGS). Primary molecular test; positive in the great majority of PV cases. Ash Publications

12. JAK2 exon 12 mutation test. Checked when V617F is negative but PV is still suspected. PMC

13. Bone-marrow biopsy. Shows a hypercellular marrow with panmyelosis and pleomorphic, mature megakaryocytes—hallmark morphology. Medscape

14. Red-cell mass (RCM) measurement (isotope dilution). Confirms a true increase in red-cell mass, helpful in “masked PV.” PMCMerck Manuals

15. Iron studies (ferritin, transferrin saturation). Iron can be low in PV (especially if phlebotomised), which may mask the true degree of erythrocytosis. Medscape

16. Turnover markers (uric acid, ± LDH). High due to rapid marrow cell turnover; supports the picture and explains gout risk. Medscape

D) Electro-diagnostic tests

17. Pulse oximetry / arterial or venous blood gas when needed. Screens for hypoxia; if saturation is low—or if carboxyhaemoglobin/methemoglobin is high—think secondary erythrocytosis rather than PV. (P50 can be calculated in some labs to look for high-affinity haemoglobins.) Medscape

18. 12-lead ECG. Not for diagnosing PV itself, but important when chest pain, breathlessness or clot is suspected; looks for ischaemia or strain from high blood viscosity.

E) Imaging tests

19. Abdominal ultrasound. Confirms splenomegaly and tracks size over time. AAFP

20. CT/MR venography (abdomen/brain) or Doppler ultrasound. Looks for clots in deep veins, lungs, or splanchnic veins (e.g., Budd–Chiari syndrome), which are important PV complications. Nature

Non-pharmacological treatments

(15 items are “physiotherapy / mind–body / educational” as asked; each item gives Description → Purpose → Mechanism → Benefits.)

A. Physiotherapy / Exercise / Mind–Body / Educational

1. Supervised walking program
   Description: 20–40 minutes, most days.
   Purpose: Cut clot risk, improve stamina.
   Mechanism: Better blood flow, less stasis; cardiometabolic gains.
   Benefits: Fewer leg cramps, better mood and sleep.

2. Interval cycling or brisk stepping
   Description: Short bursts of faster pace with easy pace between, 2–3×/week.
   Purpose: Improve fitness safely.
   Mechanism: Trains heart/lungs without long strain.
   Benefits: Less breathlessness and fatigue.

3. Light resistance training
   Description: Bands or light weights 2–3×/week.
   Purpose: Keep muscle and bone strength.
   Mechanism: Builds muscle pump to help venous return.
   Benefits: Better balance, fewer falls.

4. Flexibility & mobility sessions
   Description: 10–15 minutes daily stretch for neck, shoulders, hips, calves.
   Purpose: Ease tension headaches and leg tightness.
   Mechanism: Improves range of motion and micro-circulation.
   Benefits: Less stiffness, better posture.

5. Balance drills
   Description: Heel-to-toe walk, single-leg stands.
   Purpose: Reduce fall risk if dizzy.
   Mechanism: Trains proprioception.
   Benefits: Safer daily movement.

6. Aquatic therapy (cool-water pool)
   Description: Gentle water walking or aerobics.
   Purpose: Exercise without heat worsening itch.
   Mechanism: Hydrostatic support reduces joint load and swelling.
   Benefits: Comfortable activity; good for joint pain.

7. Breathing training (diaphragmatic)
   Description: 5–10 minutes twice daily.
   Purpose: Calm stress, improve oxygenation sensations.
   Mechanism: Parasympathetic activation lowers heart rate and anxiety.
   Benefits: Fewer palpitations and panic-like feelings.

8. Guided mindfulness or meditation
   Description: 10 minutes daily (apps or therapist).
   Purpose: Cut stress, help with itch-scratch cycle.
   Mechanism: Lowers sympathetic arousal and perceived itch.
   Benefits: Better sleep, mood, symptom control.

9. Cognitive-behavioral therapy (CBT) for chronic itch & anxiety
   Description: 6–10 sessions.
   Purpose: Break the attention–scratch loop; coping skills.
   Mechanism: Reframes triggers, adds response options.
   Benefits: Less scratching, better quality of life.

10. Sleep hygiene plan
    Description: Regular schedule; cool, dark bedroom; limit screens; wind-down routine.
    Purpose: Ease night sweats/itch-disturbed sleep.
    Mechanism: Stabilizes circadian rhythm.
    Benefits: More daytime energy.

11. Cool-temperature self-care
    Description: Lukewarm showers, fans, breathable cotton/linen.
    Purpose: Reduce aquagenic pruritus (itch after water).
    Mechanism: Avoids mast-cell triggers by heat.
    Benefits: Less after-shower itch.

12. Oatmeal or menthol bath soaks; emollients
    Description: Colloidal oatmeal soak; menthol 1% lotion; thick moisturizer right after bathing.
    Purpose: Sooth skin nerves and seal moisture.
    Mechanism: Counter-irritation; barrier repair.
    Benefits: Itch relief; fewer scratch marks.

13. Education on clot-prevention in travel
    Description: Move every 1–2 hours; calf pumps; aisle seat; stay hydrated.
    Purpose: Prevent DVT during flights/long rides.
    Mechanism: Keeps venous blood moving.
    Benefits: Lower leg-clot risk.

14. Medication-safety education
    Description: Learn aspirin/anticoagulant rules, bleeding signs, drug–herb interactions.
    Purpose: Use therapy safely.
    Mechanism: Informed choices prevent harm.
    Benefits: Fewer ER visits for bleeding/ulcers.

15. Support group or psycho-oncology referral
    Description: In-person/online groups; counselor familiar with MPNs.
    Purpose: Reduce isolation; share tips.
    Mechanism: Social support lowers stress and symptoms.
    Benefits: Better coping and adherence.

B. Additional non-drug strategies

16. Therapeutic phlebotomy (venesection) (a procedure, not a drug)
    Description: Remove ~450–500 mL blood per session.
    Purpose: Keep Hct ≤45%.
    Mechanism: Lowers red-cell mass and viscosity.
    Benefits: Fewer clots and cardiovascular events. Strong evidence supports the ≤45% target. New England Journal of MedicineBJH

17. NB-UVB phototherapy for severe itch
    Description: Dermatology-supervised light therapy 2–3×/week for a short course.
    Purpose: Reduce aquagenic/pruritic symptoms.
    Mechanism: Modulates cutaneous nerves and immune cells.
    Benefits: Can lower itch when creams fail.

18. Smoking cessation
    Description: Quit plan, NRT/behavioral support.
    Purpose: Reduce clot and heart risks.
    Mechanism: Lowers platelet activation and vascular injury.
    Benefits: Major drop in cardiovascular events.

19. Weight management
    Description: Gentle calorie balance, dietitian input.
    Purpose: Improve blood pressure, sleep apnea, insulin resistance.
    Mechanism: Less inflammation and vascular strain.
    Benefits: Lower thrombotic risk; more energy.

20. Hydration plan
    Description: Regular water intake unless your doctor limits fluids.
    Purpose: Reduce viscosity, headaches, and leg cramps.
    Mechanism: Keeps plasma volume adequate.
    Benefits: You feel clearer and less dizzy.

21. Limit extreme heat exposure
    Description: Avoid hot tubs/saunas; cool showers.
    Purpose: Prevent vasodilation-triggered itch and faintness.
    Mechanism: Less histamine release.
    Benefits: Fewer flares.

22. Compression stockings for long standing/travel
    Description: Graduated knee-highs, 15–20 mmHg if advised.
    Purpose: Prevent pooling in legs.
    Mechanism: Improves venous return.
    Benefits: Lower DVT risk and swelling.

23. Vaccination up to date
    Description: Flu, COVID-19, pneumococcal as advised.
    Purpose: Prevent infections that raise clot risk.
    Mechanism: Avoids inflammation “hits.”
    Benefits: Fewer setbacks and hospital visits.

24. Gene-therapy awareness (education only)
    Description: Understand that gene therapy is not an approved PV treatment today.
    Purpose: Set realistic expectations; avoid unproven offers.
    Mechanism: JAK2 editing research exists but is experimental.
    Benefits: Safety and wise choices (use clinical trials only).

25. Clinical-trial screening
    Description: Ask about trials (e.g., hepcidin mimetics).
    Purpose: Access new options if standard care is not enough.
    Mechanism: Structured research with ethics oversight.
    Benefits: May reduce phlebotomy needs and improve symptoms in studies (see rusfertide below). PubMed

---

Drug treatments

1. Low-dose aspirin
   Class: Antiplatelet.
   Dose/Time: 75–100 mg once daily with food (if no ulcer/bleeding risk).
   Purpose: Prevent clots.
   Mechanism: Irreversible COX-1 block → less thromboxane A₂ → platelets less sticky.
   Side effects: Stomach upset, bleeding, ulcers. Proven to lower thrombotic events in PV. New England Journal of Medicine

2. Hydroxyurea
   Class: Cytoreductive antimetabolite.
   Dose/Time: Often 500 mg twice daily then adjust to counts.
   Purpose: High-risk PV or uncontrolled counts.
   Mechanism: Blocks DNA synthesis in fast-dividing marrow cells → fewer RBCs/platelets.
   Side effects: Mouth sores, low counts, skin/nail darkening; rare leg ulcers.

3. Ropeginterferon alfa-2b (BESREMi®)
   Class: Pegylated interferon (immune-modifying).
   Dose/Time: Common start 100–250 µg every 2 weeks, titrate; many switch to every 4 weeks once stable (follow label/clinic protocol).
   Purpose: Cytoreduction with potential disease modification (can lower JAK2 allele burden).
   Mechanism: Immune control of malignant clone; anti-proliferative.
   Side effects: Flu-like symptoms, mood change, thyroid effects, low counts. FDA-approved for PV. FDA Access DataNature

4. Peginterferon alfa-2a
   Class: Pegylated interferon.
   Dose/Time: Often 45–90 µg weekly, adjust.
   Purpose: Alternative interferon in younger pts or pregnancy planning (specialist use).
   Mechanism/Side effects: As above (class effects).

5. Ruxolitinib
   Class: JAK1/2 inhibitor.
   Dose/Time: 10 mg twice daily (typical PV start) and adjust.
   Purpose: For hydroxyurea-resistant or intolerant PV; helps hematocrit control, spleen, and symptoms (itch, night sweats).
   Mechanism: Blocks overactive JAK-STAT signals.
   Side effects: Low counts, shingles reactivation, weight gain, headache. Strong trial proof of benefit. New England Journal of MedicinePMC

6. Busulfan
   Class: Alkylating agent.
   Dose/Time: Very low intermittent dosing in older patients who cannot take other drugs.
   Purpose: Cytoreduction when HU/interferon not suitable.
   Mechanism: DNA cross-linking.
   Side effects: Prolonged cytopenias; careful specialist use.

7. Radioactive phosphorus (P-32)
   Class: Radiopharmaceutical.
   Dose/Time: Single/limited dose in selected elderly patients.
   Purpose: Legacy option when other therapies fail.
   Mechanism: Targets marrow to reduce cell production.
   Side effects: Long-term marrow suppression; leukemia risk; rarely used today.

8. Apixaban (or other DOAC)
   Class: Anticoagulant.
   Dose/Time: Apixaban 5 mg twice daily (dose adjust if criteria).
   Purpose: Treat or prevent clots (DVT/PE) when indicated.
   Mechanism: Factor Xa inhibition → prevents fibrin clot growth.
   Side effects: Bleeding; drug interactions.

9. Warfarin
   Class: Vitamin K antagonist.
   Dose/Time: Titrate to INR 2–3.
   Purpose: Alternative to DOACs; needed for some valve/antiphospholipid cases.
   Mechanism: Reduces vitamin-K-dependent clotting factors.
   Side effects: Bleeding; food/drug interactions.

10. Clopidogrel
    Class: P2Y12 antiplatelet.
    Dose/Time: 75 mg daily if aspirin-intolerant.
    Purpose: Alternative antiplatelet.
    Mechanism: Blocks ADP-mediated platelet activation.
    Side effects: Bruising, bleeding.

11. Allopurinol
    Class: Xanthine oxidase inhibitor.
    Dose/Time: 100–300 mg daily.
    Purpose: Prevent gout or high uric acid from rapid cell turnover or phlebotomy.
    Mechanism: Lowers uric acid production.
    Side effects: Rash; rare severe hypersensitivity.

12. Antihistamines (e.g., cetirizine)
    Class: H1 blocker.
    Dose/Time: 10 mg daily as needed.
    Purpose: Reduce itch.
    Mechanism: Blocks histamine receptors.
    Side effects: Sleepiness (less with newer agents).

13. SSRIs (e.g., paroxetine) for aquagenic itch
    Class: Antidepressant with anti-itch effect.
    Dose/Time: 10–20 mg daily (specialist guidance).
    Purpose: Refractory itch.
    Mechanism: Central serotonin pathways reduce itch perception.
    Side effects: Nausea, sexual dysfunction.

14. Gabapentin
    Class: Neuromodulator.
    Dose/Time: 100–300 mg at night, titrate.
    Purpose: Neuropathic-type itch or burning.
    Mechanism: Modulates calcium channels in nerves.
    Side effects: Drowsiness, dizziness.

15. Proton-pump inhibitor (PPI) when needed with aspirin/anticoagulant
    Class: Acid-suppressing.
    Dose/Time: Omeprazole 20 mg daily.
    Purpose: Protect stomach if high bleeding/ulcer risk.
    Mechanism: Blocks gastric acid pump.
    Side effects: Headache; rare long-term effects.

Note: The two cornerstones with strongest outcome data are Hct ≤45% (often achieved with phlebotomy ± cytoreduction) and low-dose aspirin if safe. Ruxolitinib and interferons are key options when cytoreduction is needed or HU fails. New England Journal of Medicine+2New England Journal of Medicine+2Nature

---

Dietary “molecular” supplements

Always review with your clinician, especially if you take aspirin or anticoagulants.

1. Omega-3 fatty acids (fish oil) – 1–2 g/day EPA+DHA with food.
   Function: anti-inflammatory; may modestly lower platelet activation.
   Mechanism: membrane lipid effects, eicosanoid balance.
   Caution: bleeding risk with high doses plus antiplatelets.

2. Vitamin D3 – 1,000–2,000 IU/day if low.
   Function: immune tone, bone health (steroids/interferon can affect bones).
   Mechanism: nuclear receptor signaling.
   Caution: check levels; avoid excess.

3. Magnesium glycinate – 200–400 mg at night.
   Function: helps cramps, sleep, constipation.
   Mechanism: smooth-muscle and nerve modulation.
   Caution: adjust if kidney disease.

4. CoQ10 – 100–200 mg/day.
   Function: mitochondrial support for fatigue.
   Mechanism: electron transport chain cofactor.
   Caution: may interact with warfarin (monitor INR).

5. Curcumin – 500–1,000 mg/day with pepperine for absorption.
   Function: anti-inflammatory.
   Mechanism: NF-κB down-regulation.
   Caution: theoretical bleeding interaction; stop before surgery.

6. Melatonin – 1–3 mg at bedtime.
   Function: sleep support if night sweats.
   Mechanism: circadian signaling.
   Caution: morning grogginess in some.

7. Psyllium fiber – 5–10 g/day in water.
   Function: bowel regularity; helps lipid profile.
   Mechanism: viscous fiber traps bile acids.
   Caution: separate from meds.

8. Probiotics (multi-strain) – per label.
   Function: gut comfort if on interferon or iron shifts.
   Mechanism: microbiome modulation.
   Caution: immunocompromised patients should ask first.

9. Green tea extract (EGCG) – 250–500 mg/day.
   Function: antioxidant; mild metabolic support.
   Mechanism: catechin pathways.
   Caution: can affect liver in high doses.

10. Avoid routine iron supplements (important note)
    Function: none for PV unless your doctor prescribes for a specific reason.
    Mechanism: extra iron can increase red-cell production in PV.
    Caution: in PV we often accept mild iron deficiency from phlebotomy to help control Hct.

---

Regenerative / stem-cell

There are no approved “stem-cell drugs” for PV. The realistic “advanced” options are:

1. Ropeginterferon alfa-2b – immune-modifying (see above). Can lower JAK2 allele burden over time in trials.

2. Peginterferon alfa-2a – similar immune-modifying effects.

3. Ruxolitinib – JAK-pathway blocker that also calms inflammatory cytokines; strong symptom control.

4. Clinical-trial hepcidin mimetic: rusfertide (PTG-300) – investigational injections that control Hct by limiting iron to the marrow; phase 2/3 data show fewer phlebotomies and better Hct control vs. placebo; regulatory reviews are ongoing. Not yet standard of care. PubMedAsc Publications

5. Allogeneic hematopoietic stem-cell transplantation (HSCT) – the only curative approach, but rarely used in PV because risks are high; considered mainly after transformation to advanced disease.

6. Clinical trials of novel JAK/IFN combinations or next-gen agents – ask your center about eligibility.

---

Procedures / surgeries

1. Therapeutic phlebotomy (venesection)
   Procedure: Remove ~500 mL blood through a vein.
   Why: Rapidly lower hematocrit to ≤45% to prevent clots. Strong evidence supports the ≤45% target. New England Journal of Medicine

2. Allogeneic HSCT
   Procedure: Replace diseased marrow with donor stem cells.
   Why: Considered only in selected advanced cases (e.g., post-PV myelofibrosis or transformation).

3. Catheter-directed thrombolysis or thrombectomy
   Procedure: Interventional radiology removes/dissolves a clot.
   Why: To treat severe DVT/PE or hepatic/mesenteric vein thrombosis.

4. Splenectomy (rare)
   Procedure: Surgical removal of enlarged, painful spleen.
   Why: For severe, refractory spleen-related symptoms or complications.

5. Vascular procedures for arterial events
   Procedure: Angioplasty/stent or bypass after heart attack/limb ischemia.
   Why: Manage complications of thrombosis; not PV-specific but sometimes needed.

---

Prevention habits

1. Keep Hct ≤45% with the plan your doctor sets. New England Journal of Medicine

2. Take low-dose aspirin if your clinician says it is safe for you. New England Journal of Medicine

3. Do regular movement (walk every day; move legs on trips).

4. Hydrate steadily; avoid heavy dehydration.

5. No smoking; avoid secondhand smoke.

6. Keep a healthy weight and manage blood pressure, cholesterol, and diabetes.

7. Cool your skin; avoid very hot water or rooms to reduce itch.

8. Use seat-time breaks (every 1–2 hours) during travel or desk work.

9. Check skin and gums for bleeding if you use aspirin/anticoagulants; report unusual bruising.

10. Stay up to date on vaccines and treat infections early.

---

When to see a doctor urgently

• New chest pain, shortness of breath, one-sided weakness, confusion, or trouble speaking (possible clot).

• New, severe leg swelling or pain (possible DVT).

• Black stools, vomiting blood, or unusual bruising (possible bleeding).

• Fever, bad chills, or infection signs while counts are low.

• Rapid growth of spleen pain/fullness, or rapid weight loss, or night sweats getting worse.

---

Foods to eat / foods to avoid

Eat more:

1. Plenty of water and watery foods (soups, fruit).

2. High-fiber plants (oats, beans, vegetables) for heart and gut health.

3. Lean proteins (fish, poultry, legumes).

4. Olive-oil-based dishes (Mediterranean style).

5. Colorful fruits/veg (antioxidants).

Limit / avoid:

1. Excess alcohol (raises bleeding risk and dehydration).
2. Very salty foods (worsens blood pressure).
3. Energy drinks / high caffeine (can worsen palpitations/anxiety).
4. Large iron-fortified supplements unless your doctor tells you (can fuel RBC production in PV).
5. Grapefruit if on certain drugs (may change levels—ask your pharmacist).

---

FAQs

1) Is PV curable?
Usually no, but it is highly manageable. HSCT can cure but is rarely used because of risk.

2) What number should I watch most?
Hematocrit. Aim ≤45% unless your doctor sets a different target. New England Journal of Medicine

3) Why do I take aspirin?
It makes platelets less sticky and lowers clot risk if it is safe for you. New England Journal of Medicine

4) I feel itchy after showers—why?
Water and heat can trigger skin nerves and mast cells in PV (aquagenic pruritus). Use lukewarm water and moisturize.

5) Can exercise cause a clot?
Regular, moderate exercise lowers clot risk. Avoid long sitting; build up slowly.

6) Do I need a special “PV diet”?
No specific PV diet. Eat heart-healthy food, drink water, and avoid extra iron unless told.

7) Are there medicines beyond hydroxyurea?
Yes—interferons (including ropeginterferon) and ruxolitinib are key options when needed. FDA Access DataNew England Journal of Medicine

8) Can these medicines shrink my spleen and help symptoms?
Ruxolitinib and interferons can reduce spleen size and improve itch/night sweats in many patients. New England Journal of Medicine

9) What about new drugs?
Rusfertide (a hepcidin mimetic) in studies reduces phlebotomy needs and controls Hct; it is not yet standard. Ask about trials. PubMed

10) Why keep my white blood cell (WBC) count controlled too?
High WBC can add to clot risk even when Hct is controlled. Your team may target WBC as well. PMC

11) Can PV turn into another disease?
A small number progress to myelofibrosis or acute leukemia over time. Good control and follow-up help lower risks.

12) Is PV inherited?
The JAK2 mutation is usually acquired during life, not passed down. Nature

13) How often will I need blood tests?
Early on, often every 2–4 weeks; later every 1–3 months—your plan may differ.

14) What about pregnancy?
PV in pregnancy needs a specialist plan—often interferon and careful monitoring (no aspirin late in pregnancy unless advised).

15) What symptoms should I track at home?
Headache, vision change, new numbness/weakness, chest pain, shortness of breath, leg pain/swelling, severe itch, night sweats, weight change, and any bleeding.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 02, 2025.

PDF Documents For This Disease Condition References